Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chaitra Ujjani

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Hematology. American Society of Hematology. Education Program|December 9, 2023
Dual-targeted regimens for the frontline treatment of CLLChaitra Ujjani
Oncology (Williston Park, N.Y.)|October 17, 2015
Targeted Approaches to the Management of Follicular LymphomaChaitra Ujjani
Clinical Advances in Hematology & Oncology : H&O|October 31, 2014
No studies have shown improved overall survival with maintenance therapyChaitra Ujjani
Future Oncology (London, England)|December 23, 2010
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trialChaitra Ujjani, Bruce Cheson
Blood|January 14, 2021
Vaccinations in CLL: implications for COVID-19Mazyar Shadman, Chaitra Ujjani
Cancer Management and Research|April 25, 2017
The clinical development of obinutuzumab for the treatment of follicular lymphomaBarbara Ma, Chaitra Ujjani
Oncotargets and Therapy|March 7, 2022
Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of TazemetostatRuben Raychaudhuri, Chaitra Ujjani
Expert Review of Anticancer Therapy|September 15, 2010
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphomaChaitra Ujjani, Bruce D Cheson
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?Chaitra Ujjani, Bruce D Cheson
Expert Opinion on Pharmacotherapy|July 10, 2012
Chronic lymphocytic leukemia: where are we and where are we going?Chaitra Ujjani, Bruce D Cheson
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Hematology. American Society of Hematology. Education Program|December 9, 2023
Dual-targeted regimens for the frontline treatment of CLLChaitra Ujjani
Oncology (Williston Park, N.Y.)|October 17, 2015
Targeted Approaches to the Management of Follicular LymphomaChaitra Ujjani
Clinical Advances in Hematology & Oncology : H&O|October 31, 2014
No studies have shown improved overall survival with maintenance therapyChaitra Ujjani
Future Oncology (London, England)|December 23, 2010
Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trialChaitra Ujjani, Bruce Cheson
Blood|January 14, 2021
Vaccinations in CLL: implications for COVID-19Mazyar Shadman, Chaitra Ujjani
Cancer Management and Research|April 25, 2017
The clinical development of obinutuzumab for the treatment of follicular lymphomaBarbara Ma, Chaitra Ujjani
Oncotargets and Therapy|March 7, 2022
Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of TazemetostatRuben Raychaudhuri, Chaitra Ujjani
Expert Review of Anticancer Therapy|September 15, 2010
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphomaChaitra Ujjani, Bruce D Cheson
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1?Chaitra Ujjani, Bruce D Cheson
Expert Opinion on Pharmacotherapy|July 10, 2012
Chronic lymphocytic leukemia: where are we and where are we going?Chaitra Ujjani, Bruce D Cheson
Pageof 5